A Randomised Open-Label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI/2N(t)RTI Therapy.

Trial Profile

A Randomised Open-Label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI/2N(t)RTI Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Raltegravir (Primary) ; Lopinavir/ritonavir; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Second Line; SECOND-LINE
  • Most Recent Events

    • 16 Jan 2014 Last checked against ClinicalTrials.gov record (Substudy trial: NCT01513122).
    • 16 Jan 2014 Last checked against ClinicalTrials.gov record (Substudy trial: NCT01513122).
    • 16 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top